Of those, 13.1%, 50.9%, and 33.7% had NCCN low, intermediate, and high risk disease, respectively. Forty-three percent of patients received upfront treatment with radical prostatectomy while the rest had radiation plus ADT. Thirty-two patients developed metastases, including 11 who died from the disease, during a median follow-up of 6 years.

The Decipher classifier was a significant predictor of metastasis at 5 years post biopsy and of prostate cancer-specific mortality.

"The 20% of patients with genomic high risk had a very high 23.4% rate of metastasis and a 9.4% rate of prostate cancer-specific mortality at 5 years," said Dr Nguyen.

Those with an intermediate Decipher score had a 5-year metastasis rate of 9.3% and a 0% 5-year prostate cancer-specific mortality rate.